The New Cervical Screening Test in Australia
The National Cervical Screening Program's (NCSP) new five-yearly Cervical Screening Test (CST) detects infection with Human papillomavirus (HPV) and replaces the two-yearly Pap test (from December 2017).
If HPV is detected, the pathology laboratory will automatically conduct a reflex liquid-based cytology (LBC) test, such as the ThinPrep Pap® test on the same sample to determine if cellular abnormalities are present.1
If both tests are performed, the pathology report will include the combined result as a risk category (low, intermediate and higher) with recommended clinical management. If any glandular abnormalities are detected, follow up in accordance with the 2016 Guidelines is required. Patients who have signs or symptoms suggestive of cervical disease are tested and managed through a different clinical pathway.1
Early changes in cervical cells rarely cause symptoms. If early cell changes progress, the most common signs include:
Vaginal bleeding between periods
Menstrual bleeding that is longer or heavier than usual
Bleeding after intercourse
Pain during intercourse
Unusual vaginal discharge
Vaginal bleeding after menopause
Excessive tiredness
Leg pain or swelling
Low back pain
Patients at any age who have signs or symptoms are recommended to have a co-test (HPV and LBC). Consider referral for the appropriate investigations to exclude genital tract malignancy. Read more here.